Kornimate/medical-research-clean huggingface dataset:
the efficacy of ultrasound-guided ozone injection in the treatment of patients with chronic low back pain

Conditions: Low Back Pain, Posterior Compartment

Summary: low back pain is a common disorder that every individual in the society is likely to meet throughout his/her life. low back pain lasting longer than 12 weeks is defined as chronic low back pain and causes serious disability in the community. conservative, pharmacological, interventional and surgical treatment options are available in its treatment. in this study, it was aimed to determine the effects of ultrasound-guided deep paravertebral periforaminal ozone injection treatment on physical examination, functional independence, quality of life and pain scores in patients with chronic low back and leg pain and to compare it with transforaminal epidural steroid injection treatment.

a total of 50 patients were included in the study. deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week. in the transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy. the patients in both groups were offered a home exercise program for therapeutic waist and abdominal muscles to do during the treatment follow-up period. patients\&#39; quality of life was evaluated with sf-36(short form-36), pain scores with vas(visüel analog scala) and functional evaluations with odi(oswestry disability index) at 15 days, 1 month, and 2 months. physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up.

Eligibility criteria:
inclusion criteria: * back and leg pain lasting longer than 3 months * diagnosis of lumbar disc herniation with advanced imaging techniques after anamnesis, - physical examination and laboratory examinations * continuation of complaints despite conservative treatment before * regular participation in the study voluntarily exclusion criteria: * being pregnant and breastfeeding * history of lomber surgery * peripheral neuropathy (diabetes, alcoholism...) * cauda equina syndrome or progressive neurologic deficit in the lower extremity * neurogenic bladder/bowel syndrome * arterial vascular disease-vascular claudication * spinal stenosis, spondylolysis, spondylolisthesis * local infection at the injection site * presence of bleeding diathesis * neuro-degenerative diseases * uncontrolled diabetes, hypertension * history of malignancy * uncontrolled psychiatric illness * bmi over 40 * allergy to injection substances

Keywords: low back pain periforaminal ozon injection transforaminal steroid injection ultrasound guided injection
care: a prospective multicenter case study to assess radiation exposure in patients treated with the penumbra coil 400

Conditions: Intracranial Aneurysms

Summary: the primary objective of this study is to gather data on the radiation exposure in patients treated with the penumbra coil 400™ system (pc 400) or conventional coils per their respective indications for use.this is a multicenter case review study of patients presenting with intracranial aneurysms who are treated with coil embolization therapy using the pc 400 or conventional coils. data for each patient are collected acutely.up to 90 patients treated with the pc 400 or conventional coils (2:1) at up to 15 centers in the usa will be enrolled.


Eligibility criteria:
inclusion criteria: * patients enrolled in the pc 400 arm must be those treated according to the cleared indication for the pc 400 system, which includes endovascular embolization of intracranial aneurysms. * patients treated with conventional coils should be treated per their ifu. * adjunctive use of stents, balloons or liquid embolics, if considered appropriate by investigators, is allowed. exclusion criteria: * pre-planned use of multiple coil systems and/or flow diverters.

Keywords: ic aneurysms, coil embolization, pc 400, radiation exposure,
a rct of telephone-supported act in ms

Conditions: Multiple Sclerosis

Summary: this study will investigate the feasibility of running a randomised controlled trial (rct) of a psychotherapy called "acceptance and commitment therapy (act)", delivered in a self-help format with additional telephone support from a therapist, for people with multiple sclerosis (ms) and low mood.

a large proportion of people with multiple sclerosis (ms) suffer from emotional problems, therefore a large percentage of people with ms would be eligible to take part in a study offering a psychotherapeutic component to address these issues. acceptance and commitment therapy (act) has been found to be effective for mood problems, and been successfully used in self-help format, but no study has thus-far examined potential for use as an effective intervention in this (ms) population. people will ms and low mood will be recruited from a neurology outpatient clinic. they will be randomized to either receive treatment as usual, or an act self-help book with 8 supportive telephone calls from a trainee clinical psychologist. measures of anxiety, depression, quality of life and physical health will be administered at baseline, post-intervention and six month follow up. a sub sample of 10 participants will be interviewed to find out their view on taking part in the study.

Eligibility criteria:
inclusion criteria: * diagnosis of ms. over 7 on the hospital anxiety and depression scale exclusion criteria: * already receiving psychotherapy
mid-life women: preventing unintended pregnancy and stis

Conditions: Reproductive Health

Summary: mid-life women, aged 35-50, are currently an underserved population in the areas of unintended pregnancy and sti prevention interventions. common perception is that women in this age range are no longer sexually active, or are past the menopause transition, but in reality, sexual activity remains stable through mid-life and into the post-menopausal years. additionally, physiological and relationship status changes (e.g. divorce or death of a partner) put these women at increased risk for both unintended pregnancy and sti's. this project developed and evaluated a theoretically-based multimedia intervention designed to assist mid-life women in protecting themselves from sexually transmitted infections and unintended pregnancy.

the primary aim of this project was to create and evaluate a theoretically-based, interactive multimedia program for women aged 35-55 to assist them in avoiding unintended pregnancy and sexually transmitted infections (stis). the intervention, titled "women's reproductive health: a guide to staying healthy," addressed these concerns across the life span and was designed to increase knowledge about (a) pregnancy risk; (b) sti risk; (c) strategies to prevent stis and unintended pregnancy; (d) influences of sexual partners on risk reduction decisions and behaviors; (e) partner communication techniques; and (f) health care provider communication techniques.overall features of the program include video, interactive tools, animations, text information pages, and various links both across and within specific modules to link related information. a feature titled "my notes" allowed the user to save content from the program into an easily retrievable repository. motivational videos featuring friendly mid-life hosts could be viewed on the first page of each module, as well as on the home page and topic introduction pages. these videos not only provided specific information about the content, they also provided message framing and set the tone of the program segment. other videos included testimonials on topics such as contraceptive methods, sexually transmitted infections, and other health information. interactive materials include an assessment checklist for sti risk, a quiz to help the user identify the types of birth control methods that best fit her lifestyle and preferences, as well as several checklists

Eligibility criteria:
inclusion criteria: * women aged 25-55. exclusion criteria: * males * women under 25 years of age and over 55

Keywords: mid-life women unintended pregnancy sti/hiv prevention intervention interactive cd-rom multimedia video
tace as an adjuvant therapy after hepatectomy for hcc

Conditions: Hepatocellular Carcinoma

Summary: investigators hypothesise that the use of transarterial chemoembolisation (tace) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival of patients with high risk factors for residual tumor. the aim of this study is to compare the survival of patients with high risk factors for residual tumor undergoing liver resection plus post-operative tace versus liver resection alone.

liver resection is the mainstay of curative treatment for hepatocellular carcinoma (hcc). however, recurrence is common after surgery and most occurs in the liver, especially for the patients with high risk factors for residual tumor, such as tumors with a diameter more than 5 cm, multiple nodules, and microvascular invasion. transarterial chemoembolisation (tace) is an effective palliative treatment for hcc. it involves the infusion of chemotherapeutic agent admixed with iodised oil followed by embolisation of the hepatic arterial flow using small particles. this procedures allows application of smaller dose of chemotherapy concentrated to the liver and thus is well tolerated with minimal side effects. the main complications of tace are liver function damage, mild feverish symptoms, vomit , etc. but most of them are reversible. we conduct a randomised controlled trial evaluating the efficacy of using tace after hepatectomy in hcc patients with high risk factors for residual tumor (tumors with a diameter more than 5 cm, multiple nodules, or microvascular invasion).

Eligibility criteria:
inclusion criteria: * hcc patients received curative hepatectomy with negative resection margin * tumors with a diameter more than 5 cm, multiple nodules, or microvascular invasion were defined as high risk factors for residual tumor and used for patient stratification. * age from 18 to 70 * child-pugh class a * asa class i to iii * ecog performance status grade 0 or 1 exclusion criteria: * patients receiving concomitant local ablation or previous tace * main portal vein tumour thrombus extraction during hepatectomy * tumour arising from caudate lobe * presence of extra-hepatic disease * impaired liver function with either clinically detected ascites, hepatic encephalopathy, serum albumin \ 50micromol/l * renal impairment with creatinine \> 200micromol/l * severe concurrent medical illness persisting \> 6 weeks after hepatectomy * history of other cancer * hepatic artery anomaly making tace not possible * allergy to doxorubicin or lipiodol * pregnant woman * informed consent not available

Keywords: hcc randomised controlled trial tace resection
predictive factors of good results after primary descemet's membrane endothelial keratoplasty (dmek)

Conditions: Endothelial Corneal Dystrophy

Summary: aim: identify predictive factors of good results after primary descemet's membrane endothelial keratoplasty (dmek) in fuchs endothelial corneal dystrophy (fecd). 82 patients (102 eyes) with fuchs endothelial corneal dystrophy (fecd) underwent dmek between march 2016 and march 2018 were analyzed. follow-up time was 12 months. the studied prognostic criteria were: pre-operative central corneal thickness (cct), cct's delta between pre and d15 post-operatively, anterior mean keratometry, pre-operative endothelial cell density (ecd) and postoperative ecd at 6 and 12 months, pre-operative visual acuity, donors' and recipients' ages, recipients' sex, rebubbling and triple procedure (dmek combined with cataract surgery).

aim: identify predictive factors of good results after primary descemet's membrane endothelial keratoplasty (dmek) in fuchs endothelial corneal dystrophy (fecd). a monocentric retrospective observational study was realized at the regional hospital center of metz-thionville, mercy hospital, metz, france. 102 eyes of 82 patients with fuchs endothelial corneal dystrophy (fecd) underwent dmek between march 2016 and march 2018 were analyzed. follow-up time was 12 months. the studied prognostic criteria were: pre-operative central corneal thickness (cct), cct's delta between pre and d15 post-operatively, anterior mean keratometry, pre-operative endothelial cell density (ecd) and postoperative ecd at 6 and 12 months, pre-operative visual acuity, donors' and recipients' ages, recipients' sex, rebubbling and triple procedure (dmek combined with cataract surgery). surgery was considered successful when best spectacle corrected visual acuity (bscva) was 0.1 logmar or less (≥0.8) 1 year postoperatively.

Eligibility criteria:
inclusion criteria: * over 18, * had advanced fecd associated with visual symptoms and reduced visual acuity . exclusion criteria: * prior intraocular surgery other than cataract * other indications for dmek surgeries than fecd, * eyes with corneal (except fecd), retinal or optic nerve diseases * per-operative difficulties (tear's graft or complicated unfolding graft) * primary graft failure (cornea that failed to clear in the presence of an attached graft) * secondary graft failure (corneal decompensation after an initial period of a functional graft)

Keywords: fuchs endothelial corneal dystrophy central corneal thickness endothelial cell density keratometry
alternative splicing and leukemia initiating cells

Conditions: Acute Myeloid Leukemia

Summary: aberrant rna splicing and mutations in spliceosome complex in acute myeloid leukaemia (aml) are frequent. it have been shown that some splicing variants had a prognostic value in aml. aml are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (lics). the aim of this study is to determine the splice variants on aml initiator cells and define a splicing pattern.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years-old * patients treated at the south lyon hospital center * patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization * patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center exclusion criteria: none
using a telemedicine approach in a genome-wide association study of atopic dermatitis - searching for novel biomarkers in clinically relevant phenotypes

Conditions: Atopic Dermatitis; Eczema; DNA

Summary: atopic eczema is a common skin disorder affecting at least 2-3% of the western population. atopic eczema cannot be cured and therefore treatment aims to alleviate the symptoms of the disease. today, many different medical treatments are available: from mild hormone creams to harsh systemic treatments. the treatment chosen depends in part on the severity of the eczema and on the treatment response of the individual. this practice may mean that some people with eczema undergo unnecessary treatment courses with associated side effects. we know today that eczema has a hereditary component, and different areas have been identified in the hereditary material that appear to play a role. although it is thought that variations in specific areas of the inheritance material may influence how eczema is expressed in the individual, the significance of these variations is far from clarified. the investigators want to increase the knowledge about atopic eczema, about the disease and how in the future we can organize the treatment of eczema based on knowledge of our genetic material. in this study, the investigators want to elucidate whether there is a correlation between specific variations in the genetic material and how the eczema is clinically expressed. in addition, the investigators want to assess whether reports with specific information about the individual's genetic material in relation to his or her lifestyle can help retain participants in research projects.


Eligibility criteria:
inclusion criteria: * informed consent has been signed * 18 years or older * resident in the usa or denmark * ad meeting the uk diagnostic criteria for atopic dermatitis * at least one visible ad lesion at the time of recruitment (as confirmed remotely through photo upload in screening) * smartphone user with daily access to internet (wifi or 3g/4g) * willing to donate a dna sample * confirmed intention to comply with study protocol procedures exclusion criteria: * female subjects that are pregnant (or plan to become so during the study period) or lactating * active dermatological condition that may confound the diagnosis of ad and/or the assessment of disease activity * unable to speak or understand english or danish * overlap with participation in interventional trials * no visible ad at time of screening * any other reasons that in the investigator's opinion could: * impede a subject's ability to complete the study period * influence the objectivity or quality of the findings of the study
evaluation of the first, second, and new drug-eluting stents in routine clinical practice

Conditions: Coronary Artery Disease; Percutaneous Transluminal Coronary Angioplasty

Summary: the objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (des), as compared with the first-,second-,third-, and fourth-generation des, in the "real world" daily practice.

consecutive patients receiving new des without a mixture of other des

Eligibility criteria:
inclusion criteria: * coronary disease amenable to percutaneous coronary intervention (pci) * no clinical and lesion limitations exclusion criteria: * patients with a mixture of several des * terminal illness with life expectancy less than 1 year * patients with cardiogenic shock

Keywords: coronary disease drug eluting stent
evaluation of residual urine after intermittent catheterisation

Conditions: Healthy

Summary: intermittent catheterization is a well-known method used for emptying the bladder. the objective of this study is to compare the residual urine after intermittent catheterisation with 2 different, hydrophilic coated, intermittent catheters. the study is a randomized, single blinded, crossover study including 24 healthy males.


Eligibility criteria:
inclusion criteria: * male * 18 years and above * a negative urine dip-stick * have signed informed written consent to participate exclusion criteria: * the test participant has previous or current congenital deformity, diseases or operation in the lower urinary tract

Keywords: residual urine hematuria ultra sound
placebo controlled efficacy and safety study of cd2475/101 40 mg tablets vs. placebo and doxycycline 100 mg capsules once daily in the treatment of inflammatory lesions of acne vulgaris

Conditions: Acne Vulgaris

Summary: the primary objectives of the study is to show cd2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in change from baseline to week 16(last observation carry forward, intent to treat) in inflammatory lesion counts.

investigator's global assessment and lesion count will be performed at each study visit.

Eligibility criteria:
inclusion criteria: * male and female subjects 12 years of age or older * acne vulgaris with facial involvement * a score of 3 (moderate) or 4 (severe) on the investigator's global assessment scale (inflammatory) * 25 to 75 inflammatory lesions (papules and pustules) on the face (including the nose) exclusion criteria: * more than two acne nodules/cysts on the face * acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne, etc.), or severe acne requiring systemic retinoid treatment * underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea * beard or facial hair which might interfere with study assessments * planning excessive exposure to sun or ultraviolet light during the study (i.e. natural or artificial sunlight, including tanning booths and sun lamp) * use of oral contraceptives solely for control of acne * liver function test alanine transaminase (alt) and/or aspartate transaminase (ast) 2.5 times above upper limit of normal * renal function test serum creatinine at 150 umol/l (17 mg/l) or higher * presence of oral or genital candidiasis or history of multiple episodes of oral or genital candidiasis * females who intend to conceive a child within 5 months following baseline visit * males who intend to conceive a child with partner during the study period * requiring concomitant use of methoxyflurane

Keywords: acne vulgaris inflammatory lesions
walnut consumption and diabetes risk

Conditions: Diabetes Mellitus

Summary: multiple nhanes surveys were combined and weighted to evaluate relationships between walnut consumption and type 2 diabetes mellitus using various independent measures of diabetes status and risk. after risks were ascertained, interactions with gender were analyzed.

background. dietary interventions and cohort studies of tree nuts lowering glucose levels for diabetes suggest a possible effect with walnuts. objective. to examine the associations between walnut consumption and diabetes risk through data from the national health and nutrition examination survey (nhanes). methods. nhanes survey data for 1999 through 2014 was pooled for adults with 24 hour recall dietary data. risk of diabetes was based on self-report, medication use, fasting plasma glucose levels, and hemoglobin a1c (hba1c) levels. individuals were characterized as reporting consumption of walnuts, mixed 'nuts', or no nuts.

Eligibility criteria:
inclusion criteria: * nhanes data from 1999-2014 with food recalls and dietary food intake exclusion criteria: * not having data on either day of the 24-hour food intake * individuals who consumed peanuts, but not other nuts on the day of recall, were excluded from the analysis

Keywords: nut consumption nhanes epidemiology plasma glucose hemoglobin a1c
compassionate use of omegaven for pediatric patients with parenteral nutrition associated liver disease

Conditions: Cholestasis; Short Bowel Syndrome

Summary: a compassionate use protocol to provide omegaven to pediatric patients with parenteral nutrition (pn) dependence and parenteral nutrition associated liver disease (pnald).

omegaven is an intravenous fat emulsion (ife) comprised of omega-3 fatty acids derived from fish oil. it will be used in an open label compassionate use treatment protocol, as an alternative to soybean oil (omega-6), as the sole ife source of parenteral nutrition in an effort to reduce and/or reverse parenteral nutrition associated liver disease. the study will evaluate the safety and efficacy of omegaven use in pediatric patients with pn dependence and pnald.

Eligibility criteria:
inclusion criteria: * pn dependence due to congenital or acquired gastrointestinal disease * predicted pn requirement for at least an additional 30 days * parenteral nutrition associated liver disease (pnald), defined as two conjugated bilirubin levels \>= 2 mg/dl at least one week apart, must be obtained to demonstrate persistence of pnald * failure to respond to standard therapies which may include cycling pn, reduction in the dose of soybean derived ife, attempts to advance enteral feeds, ursodiol, metronidazole, and avoidance of excessive caloric provision * signed parent or legal guardian informed consent exclusion criteria: * acute treatable infection (e.g. urinary tract infection, sepsis) * known allergy to egg or fish protein * contraindications to omegaven * pregnancy * serum triglyceride level greater than 400 mg/dl at baseline * history of severe hemolytic disorders or inr greater than 1.5 at baseline (inr cutoff of greater than 2 for infants less than 1 week of age)

Keywords: parenteral nutrition associated liver disease cholestasis short bowel syndrome omegaven